KLE1615 sp900066985

Taking a closer look at one member of the gut community

KLE1615 sp900066985 is a name used in genome databases for a gut bacterium. An NCBI record describes a genome reconstructed from human stool under this name. In a microbiome report, the entry may show what share of the analyzed DNA was assigned to this group. It is not a standalone disease test.

The precision of that assignment depends on the method and reference database. Bacterial 16S rRNA gene sequencing and shotgun metagenomics both examine DNA, but differ in resolution and the organisms they can detect. A species name alone does not reveal how active the organism is in the gut or how much of a particular substance it produces. The methods paper by Jovel and colleagues explains these differences; it does not validate a specific KLE1615 test.

What looking at this species can show

Gut microbes help process components of food. Some produce short-chain fatty acids that interact with the intestinal lining and immune cells, among other effects. The review by Mann and colleagues describes these mechanisms. It does not show that a particular share of KLE1615 confirms a healthy gut barrier or adequate butyrate production.

Even related bacteria differ in their functions and observed links with disease. The review of Lachnospiraceae illustrates this complexity. For a personal result, the useful lesson is that a simple division into good and bad microbes misses much of the picture. Bloating or irregular bowel movements cannot be explained by a high or low KLE1615 result alone.

Tracking this species may be interesting for research. That does not yet establish a benefit for choosing foods, probiotics, or medicines for an individual. The international consensus on microbiome testing finds insufficient evidence for its broad use in routine clinical care. Additional blood or stool markers should answer a specific medical question; combining them with a profile does not automatically make the KLE1615 result more informative.

Understanding your profile

A relative abundance describes the composition of the analyzed sample. It can rise because other groups have decreased, without an increase in the absolute number of KLE1615 bacteria. A provider’s comparison range depends on the people studied, laboratory method, and data processing. It is not the same as a medically validated target.

A result labeled optimal does not confirm a particular level of digestive function or low inflammation. Conversely, a result outside that range does not, by itself, justify treatment. Diversity is not a personal health verdict either: a number needs a meaningful comparison and a clearly defined question.

Metabolic potential and the substances actually produced are different measurements. If a report infers functions from composition, that is not a direct measurement of butyrate or other compounds. A stool sample also does not represent every region and habitat of the digestive tract equally.

Persistent symptoms deserve assessment regardless of the profile. Blood in the stool, unintentional weight loss, or persistent fever are reasons to seek medical advice promptly. An unremarkable microbiome report does not cancel out these warning signs.

What can change your result?

Diet, antibiotics, and other influences can change microbial composition. Collection, storage, shipping, and analysis matter too. The clinical methods review by Allaband and colleagues describes variation within a person and between laboratory methods. A change should therefore not immediately be read as improvement or deterioration.

Follow the collection instructions and record relevant medicines or a recent bowel preparation. Do not change your usual diet just to obtain a more favorable number, or stop necessary medication on your own. Whether another sample is worthwhile depends on the question; repeated measurements alone do not create a clinically reliable interpretation.

Frequently asked questions

What does a KLE1615 sp900066985 test measure?

In a DNA-based microbiome profile, it identifies sequences assigned to KLE1615 sp900066985 and their relative share. The provider needs to demonstrate whether its method can reliably distinguish this species from related organisms.

The name does not tell you whether living bacteria, their activity, or their metabolic products were measured separately. A typical DNA profile also does not automatically measure RNA, fungi, and viruses.

How is a KLE1615 sp900066985 sample collected?

Usually, a small stool sample is sent in the specified collection container. The required amount, stabilizing fluid, storage, and shipping arrangements vary between kits; follow the enclosed instructions.

Wash your hands before and after collection. Avoid contamination with urine or toilet water, and label the container as directed. Careful collection is a prerequisite for a usable sample, but it does not demonstrate that the test has medical value.

What can my KLE1615 sp900066985 results tell me about my health?

They initially describe one part of the microbial composition. This species’ share is not enough to determine nutrient absorption, inflammation, gut-barrier function, or gut-brain communication.

If you have symptoms, their course, associated symptoms, and your medical history matter most. These help determine whether targeted investigations would be useful.

How accurate or reliable are KLE1615 sp900066985 tests?

That cannot be given a number without details of the particular test. Relevant factors include the detection limit, reference database, ability to distinguish related species, and reproducibility. The general capabilities of modern sequencing do not replace this assessment.

Even a technically accurate measurement may be difficult to interpret medically. Analytical accuracy and clinical usefulness are separate qualities.

How often should I test KLE1615 sp900066985?

There is no established medical schedule for routinely monitoring this result. Having a baseline does not by itself justify a series of further tests.

Before repeating the test, be clear about the question it should answer and whether the result could change a useful decision. For persistent symptoms, a targeted assessment is more helpful than simply following a percentage.

Can KLE1615 sp900066985 populations change quickly?

Microbiome profiles can change over time. The sources reviewed here do not establish a reliable personal time frame for KLE1615 sp900066985 to change or stabilize.

Record relevant circumstances around a sample. Do not independently change medicines or diet simply to obtain supposedly more comparable or favorable results.

Are KLE1615 sp900066985 results diagnostic?

The relative share alone does not diagnose a disease. It also does not demonstrate resilience or a dysbiosis that requires treatment.

A profile should therefore neither replace necessary diagnostic testing nor be the sole reason for starting treatment.

How can I support KLE1615 sp900066985 after testing?

The reviewed sources do not provide a target to pursue with a particular food or supplement. A low share does not automatically mean a probiotic is missing.

Nutrition advice can be useful for specific symptoms or a limited diet. Choose steps according to your needs and the evidence supporting them, rather than trying to increase one database entry.

Sources and further reading

• Vacca M, Celano G, Calabrese FM, Portincasa P, Gobbetti M, De Angelis M (2020). The controversial role of human gut Lachnospiraceae. Microorganisms, 8(4), 573. Source

• Mann ER, Lam YK, Uhlig HH (2024). Short-chain fatty acids: Linking diet, the microbiome and immunity. Nature Reviews Immunology, 24(8), 577-595. Source

• Jovel J, Patterson J, Wang W, Hotte N, O’Keefe S, Mitchel T, Perry T, Kao D, Mason AL, Madsen KL, Wong GK (2016). Characterization of the gut microbiome using 16S or shotgun metagenomics. Frontiers in Microbiology, 7, 459. Source

• Allaband C, McDonald D, Vázquez-Baeza Y, Minich JJ, Tripathi A, Brenner DA, Loomba R, Smarr L, Sandborn WJ, Schnabl B, Dorrestein P, Zarrinpar A, Knight R (2019). Microbiome 101: Studying, analyzing, and interpreting gut microbiome data for clinicians. Clinical Gastroenterology and Hepatology, 17(2), 218-230. Source

• NCBI BioSample. KLE1615 sp900066985 MAG, SAMN34173390. Dataset

• Porcari S et al. (2025). International consensus statement on microbiome testing in clinical practice. Lancet Gastroenterology & Hepatology, 10, 154–167. Full text